Augmentation with antidepressants in schizophrenia treatment: benefit or risk
Ye-Meng Mao, Ming-Dao Zhang Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, World Health Organization Collaborating Center for Research and Training in Mental Health, Shanghai, People’s Republic of China Abstract: We focused on the application o...
Guardado en:
Autores principales: | Mao YM, Zhang MD |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e2bb9f8ea7e24f3095a4ebd48e7ec705 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012) -
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman R, et al.
Publicado: (2011) -
Examining the relationship between adherence and satisfaction with antidepressant treatment
por: Aljumah K, et al.
Publicado: (2014) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi A, et al.
Publicado: (2013) -
Influence of drug treatment with antidepressants and antipsychotics on plasma urea levels
por: Lozano Ortiz R
Publicado: (2012)